Translate this page into:
Synthesis, characterization and screening for antidepressant and anticonvulsant activity of 4,5-dihydropyrazole bearing indole derivatives
⁎Corresponding author. Tel.: +91 9923484915; fax: +91 2563257599. rxpatilpravin@yahoo.co.in (Pravin O. Patil)
-
Received: ,
Accepted: ,
This article was originally published by Elsevier and was migrated to Scientific Scholar after the change of Publisher.
Peer review under responsibility of King Saud University.
Abstract
In the present study, a series of new substituted 5-(1H-Indol-3-yl)-3-(phenyl)-4,5-dihydropyrazoline derivatives (2a–m) have been synthesized with good yield by microwave assisted synthesis. The compounds synthesized were screened for antidepressant and anticonvulsant potentialities in mice by a forced swim test and subcutaneous pentylenetetrazole (scPTZ) test, respectively. Neuro-toxicities were determined by rotarod test in albino mice. The structures of all new compounds were confirmed by IR, 1H NMR, mass spectral data, and microanalyses. The results revealed that compounds 2b, 2e and 2k were found to be potent antidepressant molecules of the series, at 20 mg/kg dose level when compared with the reference drugs imipramine and fluoxetine. Whereas, compounds 2c and 2d were found to be potent anticonvulsant molecules of this series, when compared with the reference drug diazepam. None of the synthesized compounds showed neurotoxicity.
Keywords
Pyrazoline
Microwave assisted synthesis
Anticonvulsant
Indole
Antidepressant
1 Introduction
The discovery of new effective drugs for the treatment of depression still remains a top priority as it affects approximately 21% of the world population. The World Health Organization (WHO) forecasts that; it will be the second leading cause of death by the year 2020 owing to complications arising from stress and the cardiovascular system (Lee et al., 2005). Depression is a chronic, recurring and potentially life-threatening serious illness characterized by persistent feelings of sadness, hopelessness, pessimism, guilt, loss of interest in activities and decreased energy. Conventionally, decreased levels of brain monoamines like norepinephrine, serotonin and dopamine are considered responsible for depression. Recent antidepressant agent increases the synaptic concentration of either two (5-HT and NE) or all three (5-HT, NE and dopamine (DA) neurotransmitters (Henn et al., 2004). Convulsions or epilepsy is a chronic neurological disorder characterized by the periodic and unpredictable occurrence of seizures that affects the people of all ages with the incidence of 3% in the population (Gliman et al. 2001; Ibrahim et al., 2008). At present, available antiepileptic drugs (AEDs) provide ample seizure controls in many patients, still about 28–30% of patients are estimated to be poorly treated (Yogeeswari et al., 2005). These drugs have proven to be effective in reducing convulsions as well as depression, at the same time their therapeutic efficacy is conquered by some undesirable side effects (Bialer et al., 2004; Lerer and Macciardi, 2002). These observations of existing drugs, along with the sharp rise of depressive and convulsion cases in today’s scenario, prompted research in the field of antidepressant and anticonvulsant as a major thrust area.
Microwave heating, in recent time has taken an indubitable place in organic synthesis as a very effective and ecofriendly (Green) method of activation of reaction (Loupy et al., 1998; Varma, 1999). The solvent-free microwave assisted reactions have gained popularity as they provide potentialities to work with open vessels and enhanced possibility of up-scaling the reactions on a preparative scale (Paul et al., 2002; Dandia et al., 2003; Deshayes et al. 1999).
Antidepressants and anticonvulsants are amongst the most widely utilized drugs for the treatment of CNS disorders (Aziz et al., 2009). Indole, the most useful heterocyclic nucleus has gained prominence in medicinal chemistry due to its diverse biological activities (Panda and Chaudhari, 2008, Biradar et al., 2010, Renukadevi and Biradar, 1999, Bajaj et al., 2003). Several studies have demonstrated the antidepressant potential of indole derivatives (Sing and Gautam, 1977, Patil and Bari, 2012, Ergenec et al., 1998; Varvaresou et al., 1998). Similarly numerous indole derivatives are reported to exhibit potent anticonvulsant activity (Singh et al., 1992, Popp, 1984, Sharma et al., 2010).
The 2-pyrazolines can be considered as a cyclic hydrazine moiety and are considered as an important heterocyclic scaffold for the development of potential antidepressant and anticonvulsant agents. Pyrazoline derivatives were achieved via treatment of chalcones (α,β-unsaturated ketones) with hydrazine derivatives (Parmar et al., 1974; Prasad et al., 2005). Pyrazoline nucleus has been reported to possess various pharmacological activities (Joshi et al., 2010; Jeong et al. 2004; Acharya et al., 2010). So far, various substituted pyrazoline derivatives have been synthesized and investigated for their antidepressant (Prasad et al., 2005; Gok et al., 2010; Palaska et al., 2001) and anticonvulsant activities (Parmar et al., 1974; Ozdemir et al., 2008; Aziz et al., 2009) and found high activity. Prasad et al. and Parmar et al., had reported the synthesis and antidepressant and anticonvulsant activity of 1,3,5 triphenyl 2-pyrazoline derivatives. Promising antidepressant or anticonvulsant activity of some pyrazoline derivatives prompted us to investigate them further. However, a pyrazoline ring has not appeared to be linked with indole so far. It was hypothesized that the combination of both chemical systems in one compound with a cyclic hydrazine moiety, which is prerequisite for antidepressant and anticonvulsant activity, may prove to be a breakthrough for the development of the lead molecule for future antidepressant and anticonvulsant research. These findings motivated us to link various heterocyclic moieties to synthesize a new series of pyrazoline derivatives by combining the indole moiety at the 5th position in order to evaluate the effect of this substitution on antidepressant and anticonvulsant activity. Based on the above mentioned facts, and in continuation with our research on new heterocyclic scaffold as an antidepressant (Patil and Bari, 2012), in the proposed study we aim to investigate whether indolyl pyrazoline derivatives show antidepressant and anticonvulsant activity using the forced swimming and scPTZ test, respectively.
2 Methods and materials
2.1 Chemistry
All solvents and chemicals used in the synthesis were procured from commercial suppliers and purified when necessary. All microwave assisted reactions were performed using a scientific microwave oven (Catalyst electromagnetic System) with a power of 800 W specially designed for organic synthesis. The completion of the reaction was monitored by thin layer chromatography performed on Merck precoated silica gel F254 plates. Silica gel (60–120 mesh size, Merck) was used for column chromatography. Melting points were recorded on an Elico Melting Point Apparatus using open capillary tube and were uncorrected. All NMR spectra were recorded on a Bruker Advance III, 400 MHz spectrometer with CDCl3/DMSO as solvent using tetramethyl silane (TMS) as internal reference standard, chemical shifts are reported in ppm (δ). The IR spectrum of synthesized compounds was recorded on a Schimadzu IR 48 Spectrophotometer with DRS technology. Elemental analyses were performed on a Vario-EL III CHNOS elemental analyzer. Mass spectra were recorded on a 410 Prostar Binary LC with 500 MS IT PDA detectors with direct infusion mass with ESI and APCI Negative and Positive mode ionization.
2.2 General procedure for the synthesis of indolyl pyrazoline derivatives (2a–m) using microwave
To a slurry of 1-(substituted 1H-indol-3-yl)-3-(substituted aryl)-prop-1-en-3-ones (1 mmol) and phenyl hydrazine hydrochloride (2 mmol) in 20 ml EtOH was added basic alumina (20 g) in a 100 ml beaker and mixed thoroughly. The reaction mixture was air dried and subjected to microwave irradiation for specified time at 455 W with 30 s pulse and cooled in between. The reaction progress was monitored by TLC. After completion of reaction as indicated by TLC, the reaction mixture was cooled to room temperature and extracted into an organic solvent. The in-organics were filtered off. On standing the filtrate afforded crystals of desired pyrazolines (2a–m), which were purified by column chromatography (Chloroform/Acetone 16:1 as eluant). The structures of the isolated compounds were characterized by spectral methods and microanalyses. Melting point of compounds 2a, 2b, 2c, 2e, 2g, 2k and 2m was confirmed as reported in the literature (Tsukerman et al., 1969).
2.2.1 5-(1H-Indol-3-yl)-3-(phenyl)-4,5-dihydropyrazoline (2a)
Yield: 85.46%, reaction time: 12 min; m.p.: 178–180 °C; IR (KBr): cm−1 3423 (N–H), 1614 (C⚌C), 1597 (C⚌N); 1H NMR (400 MHz CDCl3, ppm): −5.61–5.64 (dd, 1H5c), 3.31–3.36 (dd, 1H4a), 3.84–3.90 (dd, 1H4b), 6.79–6.82 (dd, 2H, NArH), 7.15–7.26 (m, 2H, NArH), 7.34 (m, 1H, NArH), 7.34–7.52 (m, 4H, C3ArH), 7.68 (d, 1H, C3ArH), 7.25 (m, 1H, C5ArH), 7.78–7.82 (m, 1H, C5ArH), 7.06 (d, 1H, C5ArH), 6.59 (s, 1H, C5ArH), 7.68 (d, 1H C5ArH), 7.96 (s, 1H, NH). 13C NMR (100 MHz CDCl3, ppm): 41.8, 57.9, 111.4, 113.6, 116.7, 118.9, 119.2, 119.9, 121.8, 112.5, 124.9, 126.9, 128.7, 128.8, 131.5, 134.2, 136.8, 145.0, 146.4. MS: m/z 337.1 (M+), 338.1(M+1). Anal. Calcd. for C23H19N3: C, 81.87; H, 5.68; N, 12.45. Found: C, 81.85; H, 5.69; N, 12.46%.
2.2.2 5-(1H-Indol-3-yl)-3-(4-methylphenyl)-4,5-dihydropyrazoline (2b)
Yield: 84.52%; reaction time: 10 min; m.p.: 175–177 °C; IR (KBr): cm−1 3414 (N–H), 1597 (C⚌C), 1554 (C⚌N); 1H NMR (400 MHz CDCl3, ppm) 2.42 (s, 3H, CH3), 5.57–5.61 (dd, 1H5c), 3.29–3.34 (dd, 1H4a), 3.82–3.87 (dd, 1H4b), 6.79–6.82 (t, 1H, NArH), 7.15–7.23 (m, 4H, NArH), 7.24–7.29 (m, 4H, C3ArH), 7.35–7.37 (d, 1H, C5ArH), 7.48–7.51 (t, 1H, C5ArH), 7.67–7.69 (t, 1H, C5ArH), 7.04 (s, 1H, C5ArH), 7.80–7.87 (m, 1H, C5ArH), 7.96 (s, 1H, NH). 13C NMR (100 MHz CDCl3, ppm): 21.4, 42.2, 57.7, 111.5, 113.6, 117.0, 118.9, 119.0, 119.1, 121.9, 112.4, 125.1, 125.8, 128.8, 129.3, 129.4, 129.5, 130.3, 136.9, 138.7, 145.6, 147.9. MS: m/z 351.2 (M+), 352.2(M+1). Anal. Calcd. for C24H21N3: C, 82.02; H, 6.02; N,11.96. Found: C, 82.05; H, 6.05; N, 11.93%.
2.2.3 5-(1H-Indol-3-yl)-3-(4-chlorophenyl)-4,5-dihydropyrazoline (2c)
Yield: 88.26%, reaction time: 15 min; m.p.: 160–161 °C; IR (KBr): cm−1 3410 (N–H), 1595 (C⚌C), 1504 (C⚌N); 1H NMR (400 MHz CDCl3, ppm) 5.61–5.65 (dd, 1H5c), 3.27–3.32 (dd, 1H4a), 3.79–3.85 (dd, 1H4b), 6.80–6.83 (m, 1H, NArH), 7.15–7.19 (m, 4H, NArH), 7.22 (d, 1H, C3ArH), 7.37–7.38 (d, 3H, C3ArH), 7.05 (s, 1H, C5ArH), 7.23–7.28 (m, 1H, C5ArH), 7.63–7.65 (d, 1H, C5ArH), 7.68–7.70 (t, 2H, C5ArH), 7.98 (s, 1H, NH). 13C NMR (100 MHz CDCl3, ppm): 41.9, 57.9, 111.5, 113.7, 116.8, 118.9, 119.2, 119.9, 121.8, 112,5, 125.0, 127.0, 128.8, 128.9, 131.5, 134.1, 136.8, 145.1, 146.4. MS: m/z 371.1 (M+), 372.1(M+1). Anal. Calcd. for C23H18ClN3: C, 74.29; H, 4.88; N, 11.30. Found: C, 74.31; H, 4.86; N, 11.27%.
2.2.4 5-(1H-Indol-3-yl)-3-(4-nitrophenyl)-4,5-dihydropyrazoline (2d)
Yield: 74.65%; reaction time: 16 min; m.p.:138–141 °C; IR (KBr): cm−1 3361 (N–H), 1598 (C⚌C), 1556(C⚌N); 1H NMR (400 MHz CDCl3, ppm) 5.91–5.94 (dd, 1H5c), 3.28–3.32 (dd, 1H4a), 3.91–3.99 (dd, 1H4b), 6.70 (s, 1H, NArH), 6.86–6.91 (m, 1H, NArH), 7.02–7.04 (m, 3H, NArH), 7.1 (s, 1H, C3ArH), 7.04–7.05 (m, 3H, C3ArH), 7.41 (s, 1H, C5ArH), 7.23–7.33 (m, 2H, C5ArH), 7.98–8.1 (t, 2H, C5ArH), 8.23 (s, 1H, NH). 13C NMR (100 MHz CDCl3, ppm): 41.0, 58.04, 112.4, 114.2, 115.2, 118.7, 119.4, 119.9, 121.8, 124.4, 124.5, 124.8, 126.5, 129.2, 137.3, 159.5, 144.0, 145.6, 146.8 MS: m/z 382.1 (M+), Anal. Calcd. for C23H18N4O2: C, 72.24; H, 4.74; N, 14.65. Found: C, 72.27; H, 4.72; N, 14.64%.
2.2.5 5-(1H-Indol-3-yl)-3-(4-methoxyphenyl)-4,5-dihydropyrazoline (2e)
Yield: 67.36%, reaction time: 16 min; m.p.: 154–156 °C; IR (KBr): cm−1 3284 (N–H), 1604 (C⚌C), 1562 (C⚌N); 1H NMR (400 MHz CDCl3, ppm) 3.39 (s, 3H, OCH3), 5.99–6.04(dd, 1H5c), 3.53–3.61 (dd, 1H4a), 3.68–3.75 (dd, 1H4b), 6.8–6.82 (m, 1H, NArH), 7.09–7.21 (m, 4H, NArH), 7.24–7.28 (m, 4H, C3ArH), 7.31–7.35 (d, 1H, C5ArH), 7.48–7.5 (t, 1H, C5ArH), 7.65–7.69 (m, 1H, C5ArH), 7.06 (s, 1H, C5ArH), 7.68–7.70 (m, 1H, C5ArH), 8.15 (s, 1H, NH). 13C NMR (100 MHz CDCl3, ppm): 41.5, 55.7, 58.6, 111.2, 113.8, 114.7, 116.6, 118.2, 119.3, 120.3, 122.4, 126.9, 127.4, 129.7, 130.3, 137.1, 144.2, 145.9, 151.2. MS: m/z 367.1 (M+), Anal. Calcd. for C24H21N3O: C, 78.45; H, 5.76; N, 11.44. Found: C, 78.46; H, 5.74; N, 11.47%.
2.2.6 5-(1H-Indol-3-yl)-3-(2-pyridyl)-4,5-dihydropyrazoline (2f)
Yield: 71.26%, reaction time: 18 min; m.p.: 160–161 °C; IR (KBr): cm−1 3400 (N–H), 1597(C⚌C), 1552 (C⚌N); 1H NMR (400 MHz, DMSO, ppm) 6.06–6.71 (dd, 1H5c), 3.62–3.73 (dd, 1H4a), 3.79–3.92 (dd, 1H4b), 6.82–6.83 (dd, 1H, NArH), 7.17–7.22 (m, 4H, NArH), 7.73–7.74 (dd, 1H, C3ArH), 7.8–7.86 (m, 2H, C3ArH), 8.67 (m, 1H, C3ArH), 7.1–7.12 (m, 2H, C5ArH), 7.24 (m, 1H, C5ArH), 7.33 (dd, 1H, C5ArH), 7.61–7.62 (m, 1H, C5ArH), 11.08 (s, 1H, NH). 13C NMR (100 MHz DMSO, ppm): 40.5, 55.2, 153.2, 143.1, 147.5, 112.8, 128.6, 117.4, 129.3, 126.1, 136.6, 123.5, 151.3, 151.9, 119, 116, 121.8, 127.3, 113, 136.1, 119.2, 111.6, 122, 120.3. MS: m/z 338.2 (M+), Anal. Calcd. for C22H18N4: C, 78.08; H, 5.36; N, 16.56. Found: C, 78.07; H, 5.38; N, 16.55%.
2.2.7 5-(1H-Indol-3-yl)-3-(2-naphthyl)-4,5-dihydroisoxazoline (2g)
Yield: 79.43%, reaction time: 16 min; m.p.: 203–204 °C; IR (KBr): cm−1 3211 (N–H), 1606 (C⚌C), 1578 (C⚌N); 1H NMR (400 MHz CDCl3, ppm) 6.03–6.13 (dd, 1H5c), 3.51–3.77 (dd, 1H4a), 3.69–3.84 (dd, 1H4b), 6.81–6.83 (m, 1H, NArH), 7.13–7.17 (m, 4H, NArH), 8.51–8.53 (m, 2H, C3ArH), 7.84–7.87 (dd, 1H, C3ArH), 7.89–7.91 (m, 2H, C3ArH), 7.51–7.53 (m, 2H, C3ArH), 7.05 (s, 1H, C5ArH), 7.21–7.26 (m, 1H, C5ArH), 7.62–7.67 (d, 1H, C5ArH), 7.69–7.71 (m, 2H, C5ArH), 8.15 (s, 1H, NH). 13C NMR (100 MHz CDCl3, ppm): 41, 57.2, 151.2, 143.6, 113.2, 126.6, 116.8, 128.4, 127.1, 126.7, 133.4, 136, 128.2, 126, 116.3, 127.1, 136.6, 118.9, 111.2, 122.3, 120.2. MS: m/z 387.1 (M+). Anal. Calcd. for C27H21N3: C, 83.69; H, 5.47; N, 10.84. Found: C, 83.68; H, 5.45; N, 10.87%.
2.2.8 5-(5-bromo-1H-Indol-3-yl)-3-(phenyl)-4,5-dihydropyrazoline (2h)
Yield: 72.85%, reaction time: 18 min; m.p.: 197–198 °C; IR (KBr): cm−1 3418 (N–H), 1606 (C⚌C), 1583 (C⚌N); 1H NMR (400 MHz CDCl3, ppm) 5.81–5.88 (dd, 1H5c), 3.34–3.39 (dd, 1H4a), 3.88–3.96 (dd, 1H4b), 6.91 (s, 1H, NArH), 6.85–6.9 (m, 1H, NArH), 7.01–7.05 (m, 3H, NArH), 7.13 (s, 1H, C3ArH), 7.66–7.69 (m, 4H, C3ArH), 7.21–7.3 (dd, 2H, C5ArH), 7.32–7.38 (t, 2H, C5ArH), 7.13–7.86, 7.99 (s, 1H, NH). 13C NMR (100 MHz CDCl3, ppm): 41.8, 57.2, 111.4, 113.6, 116.8, 118.1, 119.3, 120.0, 121.9, 124.9, 127.0, 128.7, 131.6, 134.3, 136.9, 145.2, 146.6. MS: m/z 417.1 (M+). Anal. Calcd. for C23H18BrN3: C, 66.36; H, 4.36; N, 10.09. Found: C, 66.38; H, 4.37; N, 10.11%.
2.2.9 5-(5-methoxy-1H-Indol-3-yl)-3-(phenyl)-4,5-dihydropyrazoline (2i)
Yield: 77.74%, reaction time: 17 min; m.p.: 187–188 °C; IR (KBr): cm−1 3245 (N–H), 1600 (C⚌C), 1610 (C⚌N); 1H NMR (400 MHz CDCl3, ppm) 3.71 (s, 3H, OCH3), 5.82–6.01 (dd, 1H5c), 3.52–3.66 (dd, 1H4a), 3.69–3.83 (dd, 1H4b), 6.81–6.83 (m, 1H, NArH), 7.13–7.17 (m, 4H, NArH), 7.09–7.1 (t, 1H, C3ArH), 7.32–7.36 (m, 2H, C3ArH), 7.61–7.68 (m, 2H, C3ArH), 6.72 (dd, 1H, C5ArH), 7.05 (d, 1H, C5ArH) 7.23–7.25 (m, 2H, C5ArH), 8.10 (s, 1H, NH). 13C NMR (100 MHz CDCl3, ppm): 41.23, 55.8, 57.12, 111.6, 113.1, 116.5, 119.0, 119.6, 119.8, 121.7, 124.5, 126.8, 128.5, 131.6, 134.4, 136.6, 145.6, 146.5, 155.0. MS: m/z 368.23 (M+), Anal. Calcd. for C24H21N3O: C, 78.45; H, 5.76; N, 11.44. Found: C, 78.49; H, 5.75; N, 11.42%.
2.2.10 5-(1H-Indol-3-yl)-3-(2-pyrolyl)-4,5-dihydropyrazoline (2j)
Yield: 70.36%, reaction time: 18 min; m.p.:201–202 °C; IR (KBr): cm−1 3212 (N–H), 1603 (C⚌C), 1596(C⚌N); 1H NMR (400 MHz CDCl3, ppm) 13.03 (s, 1H, NHpyr), 5.99–6.12 (dd, 1H5c), 3.49–3.67 (dd, 1H4a), 3.68–3.81 (dd, 1H4b), 6.8–6.82 (d, 1H, NArH), 7.13–7.26 (m, 4H, NArH), 6.13–6.15 (t, 1H, C3ArHpyr), 6.5–6.53 (dd, 1H, C3ArHpyr), 6.91–6.94 (m, 1H, C3ArHpyr), 7.65–7.69 (m, 2H, C5ArH), 7.06 (s, 1H, C5ArH), 7.88–7.91 (m, 2H, C5ArH), 8.10 (s, 1H, NHind). 13C NMR: 41.2, 57, 154.2, 143, 114.1, 129.3, 117.2, 117.9, 111.6, 110.1, 118.3, 116.1, 122.5, 127.1, 136.2, 119.3, 111, 122.5, 120.2. MS: m/z 327.2 (M+), Anal. Calcd. for C21H18N4: C, 77.28; H, 5.56; N, 17.17. Found: C, 77.30; H, 5.57; N, 17.13%.
2.2.11 5-(1H-Indol-3-yl)-3-(2-thienyl)-4,5-dihydropyrazoline (2k)
Yield: 68.82%, reaction time: 18 min; m.p.:192–194 °C; IR (KBr): cm−1 3243 (N–H), 1592(C⚌C), 1576 (C⚌N); 1H NMR (400 MHz CDCl3, ppm) 6.06–6.12 (dd, 1H5c), 3.51–3.61 (dd, 1H4a), 3.69–3.78 (dd, 1H4b), 6.81–6.83 (d, 1H, NArH), 7.14–7.24 (m, 4H, NArH), 7.43–7.49 (m, 2H, C3ArHthienyl), 7.55–7.57 (dd, 1H, C3ArHthienyl), 7.61–7.67 (m, 2H, C5ArH), 7.71–7.79 (m, 3H, C5ArH), 8.14 (s, 1H, NH). 13C NMR (100 MHz CDCl3, ppm): 41.5, 57.2, 154.6, 143.3, 113.1, 129, 117.1, 143, 126.4, 127, 127.1, 125.3, 116.3, 122.4, 127.3, 136.1, 119.1, 111.4, 122.2, 120.4. MS: m/z 344.1 (M+), Anal. Calcd. for C21H17N3S: C, 73.44; H, 4.99; N, 12.23. Found: C, 73.47; H, 4.97; N, 12.24%.
2.2.12 5-(1H-Indol-3-yl)-3-(4-hydroxyphenyl)-4,5-dihydropyrazoline (2l)
Yield: 77.13%, reaction time: 16 min; m.p.:173–174 °C; IR (KBr): cm−1 3316 (N–H), 3408 (OH), 1602 (C⚌C), 1558 (C⚌N); 1H NMR (400 MHz CDCl3, ppm) 11.81 (s, 1H, OH), 6.12–6.19 (dd, 1H5c), 3.56–3.63 (dd, 1H4a), 3.71–3.85 (dd, 1H4b), 6.63 (s, 1H, NArH), 6.85–6.89 (m, 1H, NArH), 7.03–7.05 (m, 3H, NArH), 7.21 (d, 1H, C3ArH), 7.07–7.11 (m, 3H, C3ArH), 7.26–7.38 (m, 3H, C5ArH), 7.96–8.0 (m, 2H, C5ArH), 8.15 (s, 1H, NH). 13C NMR: 41.3, 57.5, 154.6, 143.2, 113.9, 129.2, 117, 126.3, 130.7, 116, 159.7, 116.3, 127.6, 136.6, 119.4, 111.3, 122.1, 120.1. MS: m/z 354.5 (M+), Anal. Calcd. for C23H19N3O: C, 78.16; H, 5.42; N, 11.89. Found: C, 78.17; H, 5.41; N, 11.91%.
2.2.13 5-(1H-Indol-3-yl)-3-(4-bromophenyl)-4,5-dihydropyrazoline (2m)
Yield: 75.39%, reaction time: 17 min; m.p.:179–181 °C; IR (KBr): cm−1 3329 (N–H), 1602 (C⚌C), 1586 (C⚌N); 1H NMR (400 MHz CDCl3, ppm) 5.61–5.65 (dd, 1H5c), 3.26–3.31 (dd, 1H4a), 3.79–3.85 (dd, 1H4b), 6.8 (s, 1H, NArH), 6.82–6.9 (m, 1H, NArH), 7.01–7.04 (m, 3H, NArH), 7.13 (s, 1H, C3ArH), 7.03–7.05 (m, 3H, C3ArH),7.4 (s, 1H, C5ArH), 7.21–7.3 (m, 2H, C5ArH), 7.67–7.7 (m, 2H, C5ArH), 6.80–7.70, 7.99 (s, 1H, NH). 13C NMR (100 MHz CDCl3, ppm): 41.5, 57.6, 111.2, 113.1, 116.3, 117.4, 120.4, 120.8, 121.3, 122.2, 125.7, 129.3, 129.8, 131.3, 131.9, 133.4, 135.8, 143.6, 147.4. MS: m/z 416.31 (M+), Anal. Calcd. for C23H18BrN3: C, 66.36; H, 4.36; N, 10.09. Found: C, 66.39; H, 4.35; N, 10.11%.
2.3 Antidepressant activity
The synthesized compounds were screened for their antidepressant activity using the forced swimming test (FST) (Porsolt et al., 1977). Adult male albino Swiss-Webster (20 ± 2 g) mice were used with free access to food and water. They were housed in a group of six. The approval of the Institutional Animal Ethics Committee (IAEC) of R. C. Patel Institute of Pharmaceutical education and Research Shirpur (Maharashtra, India) was taken prior to the start of the experiments. On the test day, mice were dropped one at a time into glass cylindrical container (diameter 10 cm, height 25 cm), containing approximately 20 cm of water at 25±1 °C temperature. Water was replaced between every trial. On this day, mice were assigned into different groups (n = 6–9 for each group). The synthesized compounds (100 mg/kg), Imipramine (20 mg/kg), and Fluoxetine (20 mg/kg) suspended in aqueous Tween 80 (0.5%) were injected as intraperitoneally (ip) [n = 6]. Control animals received 0.5% aqueous solution of Tween 80. Then, after 1/2 h the mice were dropped individually into the glass cylinder and left in the water for 6 min. After the first 2 min of the initial vigorous struggling, the animals were immobile. A mouse was judged immobile if it floated in the water in an upright position and made only slight movements in order to prevent sinking. The duration of immobility was recorded during the last 4 min of the 6-min test. Statistical analysis was performed by one-way ANOVA followed by Dunnett’s test to evaluate the results. The results of FST are summarized in Fig. 1.
The effect of treatment with 2a–m (100 mg/kg, i.p.), imipramine (20 mg/kg, i.p.) and fluoxetine (20 mg/kg, i.p.) on the immobility time in FST (Data were analysed by one way ANOVA followed by Dunnet’s test. n = 6. Values are represented as mean ± S.E.M. compared with control group. P < 0.05 was considered statistically significant, ∗∗∗P < 0.001, ns = not significant. # indicates compounds 2b, 2e and 2k were employed at the dose of 20 mg/kg.
2.4 Anticonvulsant activity
The title compounds were tested for anticonvulsant activity against the PTZ induced convulsions in mice according to the reported method (Turner, 1965; Krall et al., 1978). All the solutions of standard drugs and PTZ were prepared in 0.9% sodium chloride solution. The test compounds were administered in the form of suspension made up of 0.5% Tween 80 in 0.9% sodium chloride solutions. All of the test compounds (100 mg/kg) were administered intra-peritoneally in a volume of 0.01 ml/g for mice at doses. Pentylenetetrazole (80 mg/kg) dissolved in 0.9% sodium chloride solution was administered in the posterior midline of the mice and the onset and severity of convulsions were noted for the control group. The test group was administered with the selected compounds 0.5 h prior to the administration of PTZ. The absence or presence of an episode of clonic convulsions was taken as the end point. The data were analysed by one-way ANOVA followed by Dunnett’s test using Graph Pad Prism software. All the values were expressed as mean ± SEM. Comparison of anticonvulsant activity by the PTZ induced seizure method (compared with standard) for compounds 2a–m are shown in Table 2.
| Compound | Ar | R | Yield (%)a | m.p. (°C) |
|---|---|---|---|---|
| 2a |
|
H | 85.46 | 178–180 |
| 2b |
|
H | 84.52 | 175–177 |
| 2c |
|
H | 88.26 | 160–161 |
| 2d |
|
H | 74.65 | 138–141 |
| 2e |
|
H | 67.36 | 154–156 |
| 2f |
|
H | 71.26 | 160–161 |
| 2g |
|
H | 79.43 | 203–204 |
| 2h |
|
Br | 72.85 | 197–198 |
| 2i |
|
OCH3 | 77.94 | 187–188 |
| 2j |
|
H | 70.36 | 201–202 |
| 2k |
|
H | 68.82 | 192–194 |
| 2l |
|
H | 77.13 | 173–174 |
| 2m |
|
H | 75.39 | 179–181 |
| Treatment | Onset time clonic convulsion durationb ± SEM (s) | Neurotoxicity |
|---|---|---|
| Vehicle + PTZ | 60.33 ± 1.62 | ND |
| Diazepam + PTZ | 128.8 ± 2.33 | – |
| 2a + PTZ | 74.0 ± 2.33 | – |
| 2b + PTZ | 61.67 ± 1.70ns | ND |
| 2c + PTZ | 116.3 ± 1.54 | – |
| 2d + PTZ | 109.8 ± 2.86 | – |
| 2e + PTZ | 65.6 ± 3.46ns | ND |
| 2f + PTZ | 93.5 ± 3.27 | – |
| 2g + PTZ | 80.6 ± 4.59∗∗∗ | ND |
| 2h + PTZ | 99.0 ± 2.76 | – |
| 2i + PTZ | 74.3 ± 3.42 | – |
| 2j + PTZ | 96.5 ± 3.39 | ND |
| 2k + PTZ | 90.6 ± 2.14 | ND |
| 2l + PTZ | 82.6 ± 3.62 | ND |
| 2m + PTZ | 103.3 ± 4.24 | – |
| 2c + PTZa | 111.7 ± 2.4 | – |
| 2d + PTZa | 102.8 ± 3.45 | – |
| 2m + PTZa | 97.8 ± 3.54 | – |
Compounds 2a–m were administered at a dose of 100 mg/kg.
ND indicates not done; A dash (–) indicates non neurotoxic.
2.5 Neurotoxicity screening
Rotarod test has been performed to detect the minimal motor deficit in mice (Vogel, 2002). The animal was placed on a 3.2 cm diameter knurled rod rotating at 6 rpm. Normal mice can remain on a rod rotating at this speed indefinitely. Neurological toxicity is defined as the failure of the animal to remain on the rod for 1 min (Table 2).
3 Results and discussion
3.1 Chemistry
The synthesis of the titled compounds (2a–m) has been carried out as being depicted in (Scheme 1). The starting compound 3 formyl indole (Organic Syntheses, 1963) and substituted indolyl chalcones 1a–m (Panda and Chaudhari, 2008) were prepared according to the known procedures. Finally, the mixture of substituted chalcones 1a–m and phenyl hydrazine hydrochloride was irradiated under microwave without solvent to afford corresponding indolyl pyrazoline derivatives 2a–m. All the synthesized compounds were characterized by their physical (Table 1), and spectral data.
Synthesis of 3-(1,3-diphenyl-4,5-dihydro-1H-pyrazol-5-yl)-1H-indole derivatives (2a-m) under microwave.
The IR spectra of the pyrazoline derivatives 2a–m exhibited C⚌N stretching vibration in the region of 1626–1516 cm−1. Disappearance of the carbonyl (C⚌O) peak at around 1710–1650 cm−1 revealed the formation of indolyl pyrazolines. In the 1H NMR spectrum, C4 (H4a, H4b) and C5 (H5c) protons of the pyrazoline ring exhibited doublets of doublets at 3.29–3.39 (δ ppm, H4a), 3.80–3.87 (δ ppm, H4b) and 5.60–5.69 (δ ppm, H5c), respectively, confirms the formation of the pyrazoline ring.
3.2 Antidepressant activity
The forced swimming test is a behavioral test used to predict the efficacy of antidepressant treatments (Porsolt et al., 1977). It has good predictive value for antidepressant potency in humans because of its sensitivity and selectivity (Willner and Mitchell, 2002). As depicted in Fig. 1, all of the compounds except 2d significantly reduced the immobility times at a dose of 100 mg/kg compared with a control (P < 0.001). The immobility time of the mice treated with 2d did not statistically differ from the control value (control, 93.17 ± 3.94 s; 2d, 80.67 ± 7.43 s (P < 0.05). An analysis of the antidepressant activities of compounds 2a–m (Fig. 1) showed the subsequent structure–activity relationships. Amongst the indolyl pyrazolines derivatives, the substituent group on the benzene ring appeared to greatly influence the FST activity. The presence of electron releasing groups (OCH3, CH3 and OH) on the phenyl ring of indolyl pyrazolines showed promising antidepressant activity. Whereas substitution of the methoxy group at the 5th position of the indole ring retains the antidepressant activity. Amongst the compounds, 5-(1H-Indol-3-yl)-3-(4-methoxyphenyl)-4,5-dihydropyrazoline (2e), 5-(1H-Indol-3-yl)-3-(4-methylphenyl)-4,5-dihydropyrazoline (2b) and 5-(1H-Indol-3-yl)-3-(2-thienyl)-4,5-dihydropyrazoline (2k) were found to be the most active antidepressant compounds and significantly reduced the duration of immobility times at 100 mg/kg dose level when compared to the control (P < 0.001). Moreover active compounds, 2b, 2e and 2k at the dose of 20 mg/kg i.p also exhibited significant antidepressant activity compared with imipramine and fluoxetine (P < 0.001). Comparing derivatives with different halogen substituents on the benzene ring, their activity order was Cl > Br > NO2 and it resulted in a decrease in antidepressant effect of existing pyrazoline derivatives. Atom bromine on the phenyl ring gave the same contribution to the antidepressant activity compared to Br atom at the 5th position of indole of the target compounds. Replacement of phenyl ring by heterocyclic nucleus on the proposed scaffold increases antidepressant activity and their activity order was thienyl > pyrrole > pyridine. Derivatives with an electron donating group on the phenyl ring of indolyl pyrazoline appear to be a more promising structural feature than with an electron withdrawing group for antidepressant like effects.
3.3 Anticonvulsant activity
The synthesized compounds 2a–m were also evaluated for anticonvulsant activity against PTZ induced seizures in mice and the results from these experiments are shown in Table 2.
Compounds 2c and 2d exhibited the most protective class of the tested compounds and other compounds 2f, 2j, 2h, 2k and 2m exhibited a moderate protection against clonic seizures induced by injection of scPTZ. While evaluating the anticonvulsant activity, it was observed that compounds carrying an electron withdrawing group (2c, 2d and 2m) on the phenyl ring C3 of pyrazoline had shown profound activity in comparison to compounds having electron releasing group (2b, 2e and 2l). Some selected compounds have been further tested for their neurotoxicity using the rotarod toxicity test. None of the synthesized compounds showed neurotoxicity as shown in Table 2.
4 Conclusion
In summary, we have reported a simple, eco-friendly, high yielding microwave assisted method for the synthesis of indolyl pyrazoline derivatives, as a novel candidate for antidepressant as well as anticonvulsant. Compounds 2b, 2e and 2k induced amazing antidepressant activity compared to standard drugs at the dose of 20 mg/kg. Other compounds 2f, 2i and 2j furnished good antidepressant activity. Generally, derivatives with an electron donating group on the phenyl ring of indolyl pyrazoline possess remarkable antidepressant activity. Moreover, compounds 2c and 2d revealed the most protective class of the tested compounds against clonic seizures induced by scPTZ. It is worth aphorism that the compounds having electron withdrawing substituent at the phenyl ring of indolyl pyrazoline exhibited a remarkable anticonvulsant activity. Consequently, such compounds would signify a fruitful matrix for the development of a new class of anticonvulsant and antidepressant agent and would warrant further investigation and derivatization as a promising scaffold.
Acknowledgments
The authors duly acknowledge the support from AICTE, New Delhi, India, through the Research Promotion Scheme No. 8023/RID/RPS-41PVT/2011-2012. Authors are thankful to Dr. S.J. Surana, Principal of the institute for providing research facilities to carry out the work. The authors gratefully acknowledge SAIF, IIT, Powai and STIC, Cochin University, Cochin and SAIF, IIT, Chennai for spectral data.
References
- Eur. J. Med. Chem.. 2010;45(2):430.
- Eur. J. Med. Chem.. 2009;44:3480.
- Indian J. Chem.. 2003;42B:1723.
- Epilepsy Res.. 2004;61:1.
- Eur. J. Med. Chem.. 2010;45:4074.
- Heterocycl. Commun.. 2003;9:415.
- Tetrahedron. 1999;55:10851.
- Eur. J. Med. Chem.. 1998;33(2):143.
- Med. Chem. Res.. 2010;19(1):94.
- Gliman, A.G., Hardman, J.G., Limbird, L.E. 2001. The Pharmacological Basis of Therapeutics. Mc. Graw-Hill, New York, pp. 521.
- Drug Discovery Today. 2004;1:407.
- J. Pharmacol. Toxicol.. 2008;2:351.
- Bioorg. Med. Chem. Lett.. 2004;14(11):2715.
- Bioorg. Med. Chem. Lett.. 2010;20(12):3721.
- Epilepsia. 1978;19:409.
- Am. Soc. Exp. Neuro Ther.. 2005;2:590.
- Int. J. Neuropsychopharmacol.. 2002;15:255.
- Synthesis 1998:1213.
- Organic Syntheses, Coll. Vol. 4, 1963, 539.
- Arch. Pharm.. 2008;341:701.
- Eur. J. Med. Chem.. 2001;36(6):539.
- Ind. J. Pharm. Sci.. 2008;208
- J. Pharm. Sci.. 1974;63:1152.
- J. Chem.. 2012;2013:1.
- Tetrahedron Lett.. 2002;43:4261.
- J. Heterocycl. Chem.. 1984;21(2):617.
- Nature. 1977;266:730.
- Bioorg. Med. Chem. Lett.. 2005;15(22):5030.
- Indian J. Heterocycl. Chem.. 1999;9:107.
- J. Heterocycl. Chem.. 2010;47(3):491.
- Arzneimittelforschung. 1977;27(10):2002.
- Arch. Pharm. Res.. 1992;15(3):272.
- Chem. Heterocycl. Compd.. 1969;5(2):268.
- Screening Methods in Pharmacology. New York and London: Academic Press; 1965. pp. 34
- Green Chem.. 1999;43
- Farmaco. 1998;53(5):320.
- Drug Discovery and Evaluation-Pharmacological Assys (2nd ed). Germany: Springer; 2002. pp. 398
- Behav. Pharmacol.. 2002;13:169.
- J. Med. Chem.. 2005;48:6202.
